Atossa Therapeutics, Inc. (ATOS) shareholders
Close on Nov 17, 2026Market cap $18.96MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ATOS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 361,747 | 3.62% | $698.17K | +12,651 | 0.00% |
| Ameriprise Financial Inc | 258,234 | 2.59% | $498.39K | +3,100 | 0.00% |
| BlackRock, Inc. | 164,358 | 1.65% | $317.21K | +31,189 | 0.00% |
| Renaissance Technologies LLC | 132,043 | 1.32% | $254.84K | +23,036 | 0.00% |
| Geode Capital Management, LLC | 92,382 | 0.93% | $178.34K | −4,679 | 0.00% |
| UBS Group AG | 82,620 | 0.83% | $159.46K | −9,414 | 0.00% |
| Jane Street Group, LLC | 56,602 | 0.57% | $109.24K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 52,583 | 0.53% | $101.49K | +348 | 0.00% |
| Millennium Management LLC | 46,508 | 0.47% | $89.76K | −20,231 | 0.00% |
| State Street Corp | 39,761 | 0.40% | $76.74K | – | 0.00% |
| Northern Trust Corp | 20,249 | 0.20% | $39.08K | +1,025 | 0.00% |
| Susquehanna International Group, Llp | 15,574 | 0.16% | $30.06K | New | 0.00% |
| Morgan Stanley | 12,345 | 0.12% | $23.83K | −3,857 | 0.00% |
| Vanguard Global Advisers, LLC | 3,089 | 0.03% | $5.96K | – | 0.00% |
| Jones Financial Companies Lllp | 2,061 | 0.02% | $3.88K | – | 0.00% |
| Royal Bank of Canada | 1,994 | 0.02% | $4.00K | +1,350 | 0.00% |
| MCF Advisors LLC | 1,066 | 0.01% | $2.06K | New | 0.00% |
| Osaic Holdings, Inc. | 587 | 0.01% | $1.13K | – | 0.00% |
| JPMorgan Chase & Co | 390 | 0.00% | $772 | +7 | 0.00% |
| Rockefeller Capital Management L.P. | 333 | 0.00% | $643 | −20 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 31 | 1M | 13.5% | 5 / 9 | 8 / 7 | 0M | 0M |
| Q1 2026 | 33 | 1M | 12.4% | 33 / 0 | 0 / 1 | 1M | 0M |
| Q4 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q3 2025 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q2 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
15 funds held ATOS in Q2 2026, 55% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ATOS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 256,137 | 2.57% | $494.34K | 0.00% | Jun 30, 2026 |
| Columbia Small Cap Value Discovery Fund | 201,434 | 2.02% | $416.97K | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 99,071 | 0.99% | $191.21K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 46,409 | 0.47% | $242.72K | 0.00% | May 31, 2026 |
| Columbia Variable Portfolio - Small Cap Value Discovery Fund | 36,383 | 0.36% | $70.22K | 0.02% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 29,203 | 0.29% | $56.36K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 14,382 | 0.14% | $75.22K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 12,643 | 0.13% | $66.12K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 6,539 | 0.07% | $12.62K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 4,211 | 0.04% | $22.02K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 1,986 | 0.02% | $3.83K | 0.00% | Jun 30, 2026 |
| Diversified Equity Alpha Master Portfolio | 952 | 0.01% | $1.84K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -750 | -0.01% | -$1.45K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Steven C. Quay | President & CEO, Director | 89,521 | 0.90% | Mar 31, 2026 |
| Mark James Daniel | Chief Financial Officer | 63,000 | 0.63% | Mar 30, 2026 |
| Heather Rees | Chief Financial Officer | – | – | May 16, 2025 |
| Richard I. Steinhart | Director | 10,000 | 0.10% | May 14, 2026 |
| Jonathan Finn | Director | 11,666 | 0.12% | May 14, 2026 |
| Tessa Cigler | Director | 10,000 | 0.10% | May 14, 2026 |
| Shu-Chih Chen | Director | 11,483 | 0.12% | May 14, 2026 |
| Stephen J. Galli | Director | 10,006 | 0.10% | May 14, 2026 |
| H. Lawrence Remmel | Director | 12,683 | 0.13% | May 14, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Richard I. Steinhart Director | May 12, 2026 | Award | +10,000 | – | – | 10,000 |
| Stephen J. Galli Director | May 12, 2026 | Award | +10,000 | – | – | 10,006 |
| Tessa Cigler Director | May 12, 2026 | Award | +10,000 | – | – | 10,000 |
| H. Lawrence Remmel Director | May 12, 2026 | Award | +10,000 | – | – | 10,683 |
| Shu-Chih Chen Director | May 12, 2026 | Award | +10,000 | – | – | 10,000 |
| Jonathan Finn Director | May 12, 2026 | Award | +10,000 | – | – | 11,666 |
| Steven C. Quay President & CEO, Director | Mar 27, 2026 | Award | +65,000 | – | – | 88,038 |
| Mark James Daniel Chief Financial Officer | Mar 26, 2026 | Award | +63,000 | – | – | 63,000 |
| Steven C. Quay President & CEO, Director | Jan 20, 2026 | Award | +331,674 | – | – | 345,572 |
| Steven C. Quay President & CEO, Director | Jan 20, 2026 | Award | +325,203 | – | – | 339,101 |
| Steven C. Quay President & CEO, Director | May 21, 2025 | Buy | +11,239 | $0.88 | $9.89K | 13,898 |
| H. Lawrence Remmel Director | Mar 26, 2025 | Buy | +10,000 | $0.70 | $7.00K | 10,257 |
| Jonathan Finn Director | Apr 10, 2024 | Buy | +25,000 | $1.77 | $44.25K | 25,000 |
| Gregory L. Weaver Former EVP, CFO, & Director | Nov 15, 2023 | Sale | −50,000 | $0.65 | $32.50K | 55 |
| Gregory L. Weaver EVP & CFO, Director | Jun 20, 2023 | Buy | +50,000 | $0.97 | $48.50K | 50,055 |
| Gregory L. Weaver Director | Jul 2, 2021 | Tax withholding | −57,084 | $6.40 | $365.34K | 107,497 |
| Gregory L. Weaver Director | Jul 2, 2021 | Option exercise | +70,000 | $1.70 | $119.00K | 164,581 |
| Gregory L. Weaver Director | Jul 2, 2021 | Sale | −107,497 | $5.58 | $599.83K | 0 |
| Gregory L. Weaver Director | Jul 2, 2021 | Option exercise | +45,000 | $2.52 | $113.40K | 94,581 |
| Gregory L. Weaver Director | Jul 2, 2021 | Option exercise | +4,581 | $5.64 | $25.84K | 4,581 |
| Gregory L. Weaver Director | Jul 2, 2021 | Option exercise | +45,000 | $2.38 | $107.10K | 49,581 |
| Kyle Guse CFO, Gen Counsel and Secretary | Nov 15, 2017 | Buy | +8,600 | $0.34 | $2.92K | 8,600 |
| Kyle Guse CFO, Gen Counsel and Secretary | Nov 15, 2017 | Buy | +1,400 | $0.34 | $476 | 10,000 |
| H. Lawrence Remmel Director | Apr 17, 2017 | Buy | +2,500 | $0.63 | $1.58K | 3,126 |
| H. Lawrence Remmel Director | Apr 1, 2016 | Buy | +1,500 | $0.33 | $495 | 10,900 |
| Steven C. Quay President & CEO, Director, 10% owner | Mar 9, 2016 | Buy | +15,000 | $0.37 | $5.55K | 4,826,858 |
| Shu-Chih Chen Director, 10% owner | Mar 9, 2016 | Buy | +15,000 | $0.37 | $5.55K | 4,348,315 |
| Steven C. Quay President & CEO, Director, 10% owner | Feb 16, 2016 | Buy | +15,000 | $0.53 | $7.95K | 4,811,858 |
| Shu-Chih Chen Director, 10% owner | Feb 16, 2016 | Buy | +15,000 | $0.53 | $7.95K | 4,333,315 |
| Steven C. Quay President & CEO, Director, 10% owner | Jan 19, 2016 | Buy | +50,000 | $0.20 | $10.00K | 4,796,858 |
| Shu-Chih Chen Director, 10% owner | Jan 19, 2016 | Buy | +50,000 | $0.20 | $10.00K | 4,318,315 |
| H. Lawrence Remmel Director | Jun 12, 2015 | Buy | +5,400 | $1.30 | $7.02K | 9,400 |
| Gregory L. Weaver Director | May 6, 2014 | Returned to company | −24,510 | – | – | 0 |
| Richard I. Steinhart Director | May 6, 2014 | Returned to company | −22,728 | – | – | 0 |
| Richard I. Steinhart Director | Mar 1, 2014 | Award | +22,728 | – | – | 22,728 |
| Gregory L. Weaver Director | Nov 21, 2013 | Buy | +10,000 | $2.58 | $25.80K | 34,510 |
| Gregory L. Weaver Director | Oct 10, 2013 | Award | +24,510 | – | – | 24,510 |
| Shu-Chih Chen Chief Scientific Officer, Director, 10% owner | Oct 1, 2013 | Sale(10b5-1 plan) | −7,265 | $5.66 | $41.12K | 4,268,315 |
| Steven C. Quay CEO, Director, 10% owner | Oct 1, 2013 | Sale(10b5-1 plan) | −7,265 | $5.66 | $41.12K | 4,268,315 |
| Shu-Chih Chen Chief Scientific Officer, Director, 10% owner | Jul 18, 2013 | Gift | −5,000 | – | – | 478,543 |
| Shu-Chih Chen Chief Scientific Officer, Director, 10% owner | Jul 18, 2013 | Gift | −100,000 | – | – | 483,543 |
| Steven C. Quay Chief Executive Officer, Director, 10% owner | Jul 18, 2013 | Gift | −5,000 | – | – | 478,543 |
| Steven C. Quay Chief Executive Officer, Director, 10% owner | Jul 18, 2013 | Gift | −100,000 | – | – | 483,543 |
| Shu-Chih Chen Chief Scientific Officer, Director, 10% owner | May 28, 2013 | Gift | −1,000 | – | – | 583,543 |
| Steven C. Quay Chief Executive Officer, Director, 10% owner | May 28, 2013 | Gift | −1,000 | – | – | 583,543 |
| Alexander D. Cross Director | May 15, 2013 | Buy | +500 | $5.49 | $2.75K | 88,866 |
| H. Lawrence Remmel Director | Jan 8, 2013 | Buy | +1,600 | $4.20 | $6.72K | 2,000 |
| H. Lawrence Remmel Director | Jan 8, 2013 | Buy | +400 | $4.10 | $1.64K | 400 |
| H. Lawrence Remmel Director | Jan 8, 2013 | Buy | +2,000 | $4.05 | $8.10K | 2,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Atossa Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 12,270 shares on Aug 31, 2026 over the last 90 days.
Congress trades
1 trade in Atossa Therapeutics reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Roger W. Marshall KS01 · child | Bought | Oct 25, 2017 | $1K–15K | Aug 6, 2018 285 days late |
See a number that looks wrong?